|
|
||||||||
Intercollege Physiology Program, Noll Physiological Research Center, Pennsylvania State University, University Park, Pennsylvania 16802
| |
ABSTRACT |
|---|
|
|
|---|
Interleukin-1 (IL-1)
is a primary mediator of inflammation that is regulated, in part, by
the hypothalamic-pituitary-adrenal axis. The purpose of this study was
to determine if gender- or age-related differences exist in the
sensitivity of IL-1-producing cells to hydrocortisone. Peripheral blood
mononuclear cells (PBMC) isolated from men and women (21-77 yr
old) were incubated with hydrocortisone (0, 50, 100, 500, or 1,000 ng/ml) with or without lipopolysaccharide (LPS). Secretion of IL-1
and IL-1 receptor antagonist was inhibited in a dose-dependent manner
(P = 0.001) without age- or gender-related differences.
Hydrocortisone decreased soluble IL-1 receptor type II (sIL-1RII)
secretion by unstimulated cells (P = 0.0001), but it increased
secretion by LPS-stimulated cells (P = 0.0001) in all groups.
Unstimulated cell supernatants from men contained greater
concentrations of sIL-1RII than the supernatants from women (P = 0.011). Compared with men, PBMCs from women were less responsive to
hydrocortisone inhibition of sIL-1RII secretion, regardless of age
(P = 0.001), and compared with the follicular phase, sIL-1RII
secretion was lower in the luteal phase of the menstrual cycle
(P < 0.05). These data indicate that basal
secretion and glucocorticoid modulation of sIL-1RII secretion by
cultured PBMCs are gender dependent. Moreover, glucocorticoid influences on sIL-1RII secretion depend on the presence or absence of
gram-negative bacterial toxins.
interleukin-1
; soluble IL-1 receptor type II; IL-1 receptor
antagonist; human mononuclear cells
| |
INTRODUCTION |
|---|
|
|
|---|
INTERLEUKIN-1 (IL-1) is a fundamental mediator
of immune and inflammatory defense responses. However, IL-1 can also
promote host-destructive processes. For example, it induces superoxide anion release by neutrophils, which can result in edematous lung injury
and pancreatic
-cell death (16, 22). Additionally, IL-1 stimulates
collagenase and proteoglycanase secretion from synovial cells,
resulting in cartilage matrix degradation (33), and therefore has been
associated with the pathogenesis of inflammatory diseases such as
rheumatoid arthritis and lupus nephritis (12). IL-1 activity is
mediated by two agonist isoforms, IL-1
, which is mainly cell
associated and has juxtacrine actions, and IL-1
, which is the
predominant secreted protein and has paracrine and endocrine actions.
IL-1 is collectively defined as the two agonist isoforms. Because of
the diverse, potentially destructive functions of IL-1, multiple
control pathways have evolved to prevent undesirable tissue damage.
Several regulators acting at the site of inflammation modulate the biological action of IL-1. One regulatory pathway involves increased secretion of IL-1 receptor antagonist (IL-1ra) by activated monocytes. IL-1ra competitively inhibits the binding of IL-1 agonists to both type I and type II IL-1 receptors on target cells (2). Another regulatory pathway involves secretion of a soluble form of the IL-1 type II receptor (sIL-1RII), which binds secreted IL-1 before it reaches target cells thus preventing activation (8).
Glucocorticoids are potent systemic anti-inflammatory agents that are
used clinically to modulate the inflammatory response. The endogenously
produced glucocorticoid, cortisol (hydrocortisone), regulates IL-1
secretion through a feedback mechanism between the
hypothalamic-pituitary-adrenal (HPA) axis and the monocyte (4, 32).
This is most clearly demonstrated in animal models of endotoxemia,
which are associated with increased ACTH and corticosterone secretion.
IL-1 is a primary mediator of HPA axis activation, because pretreating
animals with anti-IL-1 receptor antibodies diminished the
endotoxin-induced increase in ACTH (30). Moreover, intravenous
injection of IL-1
activates the hypothalamus, increasing corticotropin-releasing factor (CRF) and ACTH secretion (29). The net
result is an IL-1-induced increase in glucocorticoid secretion, which,
in turn, inhibits IL-1
secretion by decreasing IL-1 mRNA expression
and stability (20, 21). This negative feedback loop limits inflammation
and prevents a potentially detrimental overactive immune response.
Animal studies suggest that gender-related differences exist in the
immune activation of the HPA axis. For example, central injection of
IL-1
in female rats resulted in higher plasma ACTH and
corticosterone concentrations than in males (29). In humans, age- and
gender-related differences in the sensitivity of the HPA axis to
feedback inhibition by glucocorticoids have been reported. In healthy
individuals, cortisol regulates its own secretion by inhibiting CRF and
ACTH secretion through a feedback mechanism. Heuser et al.
(17) demonstrated that dexamethasone pretreatment in women
did not inhibit CRF-stimulated secretion of ACTH and cortisol to the
same magnitude as in men. In older subjects, stimulation of the HPA
axis resulted in a more prolonged secretion of ACTH and cortisol
compared with younger subjects (17). Furthermore, cortisol infusion was
less effective at inhibiting the secretion of ACTH in older subjects
(40). Gender differences in the sensitivity of the HPA axis to feedback
inhibition by glucocorticoids are more pronounced with increasing age.
Compared with older men, cortisol concentrations in older women
remained elevated for a longer period of time after HPA axis activation
(15). Thus there is an age- and gender-related decline in
the ability to turn off the HPA axis after activation, resulting in a
stronger and more prolonged HPA response.
Paradoxically, the incidence of inflammatory diseases such as
Hashimoto's thyroiditis, systemic lupus erythmatosus, and rheumatoid arthritis is much greater in women compared with men (1). Furthermore, the risk of inflammatory diseases increases as the individual ages
(19). These outcomes may be reconciled if a reduced sensitivity to
cortisol-mediated feedback inhibition on inflammatory cytokine secretion exists in women and in the elderly compared with young men.
Although age and gender differences in the sensitivity of the HPA axis
are well documented, the sensitivity of the mononuclear cell to
inhibition by glucocorticoids has not been examined between genders or
with aging. The purpose of this study was to test the hypothesis that
secretion of the principal soluble IL-1 isoforms (IL-1
and IL-1ra)
and soluble receptor (type II) by mononuclear cells of women and older
individuals is less sensitive to inhibition by hydrocortisone than the
cells of young men.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Subjects. All subjects were healthy, not taking any medication,
and they gave an informed consent to participate in this study. Six
healthy women (28.8 ± 1.7 yr of age, not taking oral contraceptives) and six healthy men (27.5 ± 2.3 yr of age) were included in this study. Baseline data from the young men (Table
1) have been included in a previously
reported study (11). The women were tested twice, once during the
midfollicular phase and once during the midluteal phase of the
menstrual cycle. To examine the effects of age, seven healthy
postmenopausal women not receiving hormone replacement therapy (62.1 ± 1.6 yr of age) and seven healthy older men (66.2 ± 3.4 yr of age)
were recruited. Subjects representing all age and gender groups were
recruited and tested concurrently. All procedures were approved by the
Pennsylvania State University Human Investigation Review Committee.
|
Blood samples. A venous blood sample was drawn from each
subject between 0800 and 0900 via the antecubital vein into a
heparinized syringe. An aliquot of the blood was removed and
centrifuged, and the plasma was separated and frozen at
70°C
until analysis of plasma sIL-1RII and cortisol concentration. The
remaining blood sample was used for mononuclear cell isolation and
determination of IL-1 isoform and soluble receptor secretion in cell culture.
Cell isolation and culture. Peripheral blood mononuclear cells
(PBMC) were isolated by density centrifugation with Ficoll-Hypaque (Histopaque, Sigma, St. Louis, MO). The mononuclear cell layer was
aspirated and washed three times with 0.9% NaCl. The cells were
resuspended in phenol red-free RPMI supplemented with 100 U/ml
penicillin, 100 µg/ml streptomycin, 100 mM HEPES, 0.2 mM L-glutamine (all from Sigma), and 1% heat-inactivated
autologous plasma (56°C for 1 h). Sodium hydrocortisone
(Solu-Cortex, Upjohn, Kalamazoo, MI) was added to the cultures in
concentrations of 0, 50, 100, 500, or 1,000 ng/ml. In stimulated
cultures, 1 ng/ml lipopolysaccharide (LPS) Escherichia coli
(E. coli 055:B5, Sigma) was added 60 min after the
hydrocortisone. Cells were incubated in 24-well polystyrene plates
(Corning Glass Works, Corning, NY) at a density of 2.5 × 106 cells/ml for 24 h at 37°C in a humidified 5%
CO2 chamber. After incubation, the supernatants were
collected and centrifuged to remove cells, and they were frozen at
70°C until analysis of IL-1
, IL-1ra, and sIL-1RII
concentrations. All containers used for cell culture were
disposable and endotoxin free; all solutions were injectable grade or
endotoxin tested.
Cytokine measurements. The IL-1ra and sIL-1RII concentrations
were measured by ELISAs developed in our laboratory. For the IL-1ra
ELISA, 96-well high binding ELISA microtiter plates (Corning Glass
Works) were coated with 50 µl of a 20 µg/ml protein A solution (Sigma) in 15 mM Na2CO3 and 34.8 mM
NaHCO3, pH 9.6 (coating buffer), and incubated overnight at
4°C (25). The plates were washed with PBS, pH 7.0, with 0.5% Tween
20 (PBST), followed by the addition of 50 µl of 4 µg/ml of
monoclonal IL-1ra antibody (R&D Systems, Minneapolis, MN) in coating
buffer and incubated overnight at 4°C. The plates were washed with
PBST blocked with 200 µl of 1% BSA-PBS for 1 h followed by washing.
Recombinant human IL-1ra standards (R&D Systems) or culture
supernatants (100 µl) were added to the wells, and the plates were
incubated overnight at 4°C. The plates were washed followed by
sequential incubations with 100 µl of 0.2 µg/ml biotinylated
polyclonal IL-1ra antibody (R&D Systems) and conjugated
streptavidin-peroxidase (Pierce, Rockford, IL). After washing the
plates, 100 µl of 2,2'-azinobis(3-ethylbenzthiazoline-sulfonic acid) (ABTS, Sigma Chemical, St. Louis, MO) substrate was added for
60-90 min followed by a reading on a spectrophotometer at 405 nm
(Multiskan Microplate Reader, Labsystems, Needham Heights, MA). The
sensitivity of the ELISA was 30 pg/ml in RPMI. Ten nanograms per
milliliter of IL-1
or IL-1RII produced <10% interference in the assay.
The methodology for the sIL-1RII ELISA was similar to that for the
IL-1ra except for the following. The plates were not coated with
protein A before the addition of the primary antibody. The plates were
coated with 2 µg/ml of monoclonal sIL-1RII antibody (R&D Systems) in
0.1 M NaCO3, pH 8.2. The secondary antibody, biotinylated
polyclonal sIL-1RII antibody (R&D Systems), was added at 0.1 µg/ml.
The sensitivity was 15 pg/ml in RPMI. Ten nanograms per milliliter of
IL-1
or IL-1ra produced <10% interference in the assay.
IL-1
concentrations were determined by a commercially available
ELISA (Cistron Biotechnology, Pine Brook, NJ). Briefly, culture supernatants were added to antihuman monoclonal IL-1
antibody-coated plates and detected with a polyclonal rabbit anti-human antibody directed against mature IL-1
. The sensitivity of this ELISA was 10 pg/ml in RPMI. Ten nanograms per milliliter of sIL-1RII or IL-1ra
produced <10% interference in the assay. Samples from each age and
gender group were included on each ELISA plate.
Cortisol assay. Plasma cortisol was determined by a commercially available solid phase competitive inhibition RIA (Coat-A-Count, Diagnostics Products, Los Angeles, CA). The sensitivity of the RIA was 1 µg/dl in plasma samples.
Statistical analysis. Data are expressed as means ± SE. All data without hydrocortisone in the culture were analyzed by a one-way ANOVA to determine between-group differences. All data examining hydrocortisone sensitivity were normalized by expressing as a percentage of the control condition (no hydrocortisone in the culture) and analyzed by a two-way repeated measures ANOVA (group × hydrocortisone concentration). Differences in the dose response to hydrocortisone between groups were indicated by the interaction term of the two-way ANOVA. The criterion for statistical significance was set at P < 0.05. The mean of the follicular and luteal measurement for each young woman is presented unless specifically stated otherwise. Differences between follicular vs. luteal phase were assessed by paired t-tests. Analyses were performed on a Macintosh computer using SuperANOVA software version 1.11 (Abacus Concepts, Berkeley, CA).
| |
RESULTS |
|---|
|
|
|---|
IL-1 isoform and soluble receptor secretion in the absence of
hydrocortisone. In unstimulated PBMC, IL-1
secretion was
undetectable in all groups, whereas both IL-1ra and sIL-1RII were
detected. No significant age-related differences were observed in these cultures (Table 1). However, when sIL-1RII secretion was analyzed by
gender, irrespective of age, cells from the men secreted significantly greater amounts (540 ± 104 pg/ml) compared with the women (244 ± 57 pg/ml, P = 0.011, Fig.
1A). Secretion of
sIL-1RII by cells from the young women was signifcantly higher in the
follicular phase compared with the luteal phase (P = 0.048, Fig. 1B).
|
Stimulation of PBMC with LPS significantly increased both IL-1
and
IL-1ra secretion but significantly decreased sIL-1RII secretion in all
groups. There were no significant age- or gender-related differences
between the groups for the LPS-stimulated cultures.
Plasma sIL-1RII and cortisol. Plasma concentrations of sIL-1RII were also examined to determine if age or gender differences existed. Overall, plasma sIL-1RII concentrations were higher in the men (7.8 ± 0.5 ng/ml) than in the women (6.7 ± 0.2 ng/ml, P = 0.047). When stratified by age group, plasma sIL-1RII was significantly greater in the young men (8.32 ± 0.63 ng/ml) compared with the young women (6.48 ± 0.20 ng/ml, P = 0.033, Fig. 1C), but not the older men compared with the older women (P = 0.85). With the exception of one outlier in the older male group, a significant correlation was observed between in vitro sIL-1RII secretion by unstimulated cells and circulating plasma concentrations (r = 0.405, P = 0.03, data not shown).
Endogenous cortisol may influence the secretion of IL-1 isoforms by PBMC, therefore plasma cortisol concentrations were determined from the same blood used to isolate PBMC. No significant differences in plasma cortisol concentrations were detected between the groups. Plasma cortisol concentrations were highest in the older women (17.6 ± 2.4 µg/dl) and lowest in the older men (13.8 ± 2.4 µg/dl).
Hydrocortisone regulation of IL-1
secretion. IL-1
secretion in unstimulated cultures was not detectable by the methods
employed. In LPS-stimulated cultures, hydrocortisone significantly
decreased IL-1
secretion in a dose-dependent manner (P < 0.0001). As shown in Fig. 2, there were no
significant age- or gender-specific differences in the sensitivity of
PBMC to hydrocortisone. In fact, PBMC sensitivity to hydrocortisone for
IL-1
secretion was almost identical for all the groups examined.
|
Hydrocortisone regulation of IL-1ra secretion. In unstimulated
cultures, hydrocortisone significantly decreased IL-1ra secretion in a
dose-related manner (P = 0.0001). Doses of hydrocortisone in
the 50-100 ng/ml range decreased IL-1ra secretion by 60-82%, and 1,000 ng/ml of hydrocortisone nearly abolished IL-1ra secretion (Fig. 3A). There were no
significant age- or gender-specific differences in IL-1ra secretion. In
LPS-stimulated cultures, hydrocortisone significantly decreased IL-1ra
secretion over the doses examined (P = 0.0001). In contrast to
unstimulated conditions, the lower doses of hydrocortisone decreased
IL-1ra by only 30-45% (Fig. 3, A and B),
whereas 1,000 ng/ml of hydrocortisone decreased IL-1ra secretion by
~70%. Thus hydrocortisone was approximately half as inhibitory in
LPS-stimulated cultures compared with unstimulated cultures. There were
no age- or gender-specific differences in the sensitivity of PBMC to
hydrocortisone in LPS-stimulated cultures.
|
Hydrocortisone regulation of sIL-1RII secretion. Secretion of
sIL-1RII in the control cultures exhibited a biphasic response to
hydrocortisone that was dependent on gender (Fig.
4A). An intermediate dose of
hydrocortisone (100 ng/ml) significantly decreased sIL-1RII secretion
in all groups (P < 0.0005), except in the young women (P = 0.19). However, higher concentra- tions of hydrocortisone (500-1,000 ng/ml) did not cause further inhibition of sIL-1RII secretion in the cells from the men. These higher concentrations of
hydrocortisone were less effective at inhibiting sIL-1RII secretion in
the cells from the women. When the data were analyzed irrespective of
age, cells from the women exhibited a significantly different dose
response to hydrocortisone from the cells from the men (P = 0.0001).
|
As shown in Fig. 4B, hydrocortisone increased sIL-1RII secretion in LPS-stimulated cultures in a dose-dependent manner (P = 0.0001). High concentrations of hydrocortisone (500-1,000 ng/ml) increased sIL-1RII secretion considerably. For example, sIL-1RII secretion by the cells from the young men increased from 35 ± 20 to 591 ± 191 ng/ml, and the secretion by the cells from the young women increased from 143 ± 88 to 648 ± 188 ng/ml. The cells from the young women exhibited a significantly different dose response to hydrocortisone from the cells from the young men (P = 0.022).
| |
DISCUSSION |
|---|
|
|
|---|
The results of this study indicate that although hydrocortisone
influences the secretion of all IL-1-related proteins studied, only
sIL-1RII secretion was influenced in a gender-dependent manner. Mononuclear cells isolated from the men secreted more sIL-1RII under
basal (non-LPS stimulated) conditions and were more responsive to high
concentrations of hydrocortisone than the cells from the women. Age did
not affect glucocorticoid sensitivity to any of the proteins examined
under any conditions. The cells were cultured in 1% autologous plasma,
therefore it is possible that humoral factors were transferred that
influenced cellular responsiveness. However, gender-specific
differences in cytokine secretion have been observed for cells cultured
with a synthetic serum replacement (10). The finding that the
circulating concentration of sIL-1RII is greater in the men
is consistent with a previous report that IL-1
binding capacity was
higher in the plasma from the men compared with the women, and this
binding capacity correlated with plasma sIL-1RII concentration (7).
Soluble IL-1RII appears to regulate IL-1 bioavailability by binding
secreted IL-1 agonists (
or
). The addition of sIL-1RII to
cultured fibroblasts or synovial cells decreased the IL-1-induced secretion of PGE2 and collagenase (6). Additionally,
compared with wild-type controls, local phorbol 12-myristate
13-acetate-induced inflammation was reduced in transgenic mice (27).
These studies implicate sIL-1RII as a natural inhibitor of IL-1-induced inflammation.
The mechanism(s) that determines gender differences in glucocorticoid-mediated inhibition of sIL-1RII secretion would not seem to be at the level of glucocorticoid receptor expression. Although decreased receptor numbers have been reported in the liver and thymus of female rats compared with male rats (13), no gender differences have been demonstrated in the glucocorticoid receptor number or affinity in human mononuclear cells (18, 36). Alternatively, progesterone can enhance the dissociation of glucocorticoids from their receptors (35), which may result in decreased glucocorticoid responsiveness. However, the present study included postmenopausal women whose progesterone concentrations would be low, thus reducing the possibility that progesterone is competing with pharmacological concentrations of hydrocortisone. Finally, if receptor expression were the key factor, then all three IL-1-associated proteins measured in this study would exhibit sex-related sensitivity to hydrocortisone.
Glucocorticoid receptor expression in mononuclear cells has been reported to decrease with age (3) which may compromise IL-1 regulation between the HPA axis and the monocyte. However, the present data indicate that the responsiveness of mononuclear cells from subjects in their seventh decade of life (on average) is similar to cells from subjects in their third decade.
An interesting finding of this study is that LPS differentially
affected the secretion of IL-1 isoforms and sIL-1RII. Both IL-1
and
IL-1ra secretion rates were significantly increased by LPS, but
sIL-1RII secretion was decreased. These data are in accordance with
others (26, 31) that demonstrated LPS decreased sIL-1RII mRNA
expression in human mononuclear cells. Moreover, the activation state
of the cell actually reversed the influence of hydrocortisone on
sIL-1RII secretion in the present study. In unstimulated cells,
hydrocortisone decreased sIL-1RII secretion, whereas in LPS-stimulated
cells it markedly increased sIL-1RII secretion (18- to 33-fold). Brown
et al. (5) have demonstrated that LPS and dexamethasone synergistically
increase sIL-1RII secretion, although they did not report a
dexamethasone-induced effect on sIL-1RII secretion in unstimulated
cells. However, they did not detect basal levels of sIL-1RII as
demonstrated in this study and by others (9, 31).
In contrast to the present data obtained with mixed mononuclear cell cultures, Colotta et al. (9) reported that dexamethasone significantly increased sIL-1RII secretion and mRNA expression in unstimulated, purified human monocytes. Conflicting data are reported regarding sIL-1RII secretion by unstimulated T cells (23, 24). However, phytohemagglutinin- or antigen-stimulated T lymphocytes do express IL-1RII mRNA and secrete the soluble receptor (23, 24). B lymphocytes also secrete sIL-1RII, however, the contribution of B lymphocytes in an isolated mononuclear cell preparation is ~5% (34). Hydrocortisone-induced decreases in sIL-1RII secretion may involve a negative influence of lymphocytes on the monocytes. The culture conditions used in the present study do correspond to in vivo conditions because unstimulated sIL-1RII secretion correlated with plasma sIL-1RII concentrations of the subjects.
Polymorphonuclear neutrophils (PMN) also express IL-1RII and secrete a soluble form, however, regulation by LPS and glucocorticoids is different from that in mononuclear cells. LPS significantly increased sIL-1RII secretion by PMN (14), and dexamethasone increased both mRNA expression and secretion of sIL-1RII in unstimulated PMN (28). In contrast to the 60-kDa form secreted by PBMC, PMN secrete a 45-kDa form of sIL-1RII with the difference being attributed to glycosylation (9, 28). The differential regulation of sIL-1RII secretion by various cell types suggests that the function of secreted sIL-1RII may be dependent on the cellular source. It is possible that under basal conditions, circulating sIL-1RII originates from PBMC. During bacterial infection, however, the contribution of mononuclear cells declines, whereas the contribution of neutrophils increases. Van der Poll et al. (37) reported that administration of a low dose endotoxin did not change plasma concentrations of sIL-1RII, which may be due to a change in the relative contribution of PMN and PBMC to the total cellular secretion of sIL-1RII.
Counterbalancing the activity of IL-1
with specific IL-1 inhibitors
provides important regulatory control of both systemic and local
inflammation. The endogenously secreted anti-inflammatory cytokines
IL-4 and IL-13 increase both sIL-1RII and IL-1ra secretion by
mononuclear cells (9, 38, 39). In contrast, the present data
demonstrated that hydrocortisone increased sIL-1RII secretion but
decreased IL-1ra secretion in LPS-stimulated cells. Thus the mechanisms
of glucocorticoid action are different from the mechanisms controlling
regulation within the cytokine network.
Perspectives
Basal secretion of sIL-1RII by PBMC in vitro and plasma concentrations of sIL-1RII in vivo were significantly lower for the women compared with the men. Additionally, cells from the women were less responsive to regulation by hydrocortisone in terms of sIL-1RII secretion. It is well established that gender differences in the immune response exist. Women have better relative resistance to certain bacterial and viral infections than men and demonstrate increased responsiveness to a variety of antigens and mitogens. However, this increased immune responsiveness is associated with reduced tolerance of self-antigens, resulting in an increased incidence of autoimmune diseases (1). The reduced secretion and plasma concentrations of sIL-1RII observed in the women compared with the men in this study may result in an increase in the immunostimulatory and proinflammatory potential of IL-1
.
This may be one mechanism that contributes to gender-dependent
differences in the immune response.
The results of this study also indicated that the activation state of
the mononuclear cells determined how they responded to hydrocortisone
in terms of sIL-1RII secretion. During gram-negative infection,
cortisol is expected to increase sIL-1RII secretion, which, in turn,
would downregulate LPS-induced IL-1 activity. However, several
physiological stressors, including ultraviolet radiation and oxidative
stress, induce IL-1
secretion; under these circumstances, cortisol
may promote IL-1 activity by downregulating sIL-1RII.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Esther Brooks-Asplund for help with subject recruitment.
| |
FOOTNOTES |
|---|
This study was supported by a National Institutes of Health (NIH) Predoctoral Training Fellowship GM-08619 to J. M. Daun, NIH Grant AI-33414 to J. G. Cannon, and Pennsylvania State University General Clinical Research Center Grant RR10732.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: J. Cannon, 103 Noll Laboratory, Pennsylvania State Univ., University Park, PA 16802-6900 (E-mail: jgc2{at}psu.edu).
Received 11 June 1999; accepted in final form 7 October 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ahmed, SA,
Penhale WJ,
and
Talal N.
Sex hormones, immune responses, and autoimmune diseases.
Am J Pathol
121:
531-551,
1985[Abstract].
2.
Arend, WP.
Interleukin-1 receptor antagonist.
Adv Immunol
54:
167-227,
1993[ISI][Medline].
3.
Armanini, D,
Karbowiak I,
Scali M,
Orlandini E,
Zampollo V,
and
Vittadello G.
Corticosteroid receptors and lymphocyte subsets in mononuclear leukocytes in aging.
Am J Physiol Endocrinol Metab
262:
E464-E466,
1992
4.
Besedovsky, H,
Del Ray A,
Sorkin E,
and
Dinarello CA.
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones.
Science
233:
652-654,
1986
5.
Brown, EA,
Dare HA,
Marsh CB,
and
Wewers MD.
The combination of endotoxin and dexamethasone induces type II interleukin-1 receptor (IL-1rII) in monocytes: a comparison to interleukin-1
and interleukin-1 receptor antagonist (IL-1ra).
Cytokine
8:
828-836,
1996[ISI][Medline].
6.
Burger, D,
Chicheportiche R,
Giri JG,
and
Dayer J.
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II soluble receptor and hindered by type I interkeukin-1 soluble receptor.
J Clin Invest
96:
38-41,
1995.
7.
Cannon, JG,
Abad LW,
Vannier E,
and
Lynch EA.
Menstrual- and gender-dependent variations in circulating IL-1 agoinsts, and antagonists, and binding proteins.
J Leukoc Biol
63:
1-7,
1998[Abstract].
8.
Colotta, F,
Dower SK,
Sims JE,
and
Mantovani A.
The type II "decoy' receptor: a novel regulatory pathway for interleukin-1.
Immunol Today
15:
562-566,
1994[ISI][Medline].
9.
Colotta, F,
Saccani S,
Giri JG,
Dower SK,
Sims JE,
Introna M,
and
Mantovani A.
Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes.
J Immunol
156:
2534-2541,
1996[Abstract].
10.
Corwin, EJ,
and
Cannon JG.
Gonadotropin modulation of interleukin-1 secretion.
J Gender-Specific Med
2:
30-34,
1999.
11.
Daun, JM,
Ball RW,
Burger HR,
and
Cannon JG.
Aspirin-induced increases in soluble interleukin-1 type II receptor concentrations in vitro and in vivo.
J Leukoc Biol
65:
863-866,
1999[Abstract].
12.
Dinarello, CA.
Interleukin-1 and interleukin-1 antagonism.
Blood
77:
1627-1652,
1991
13.
Endres, DB,
Milholland RJ,
and
Rosen F.
Sex differences in the concentration of glucocorticoid receptors in rat liver and brain.
J Endocrinol
80:
21-26,
1979
14.
Giri, JG,
Wells J,
Dower SK,
McCall CE,
Guzman RN,
Slack J,
Bird TA,
Shanebeck K,
Grabstein KH,
Sims JE,
and
Alderman MR.
Elevated levels of shed type II IL-1 receptor in sepsis.
J Immunol
153:
5802-5809,
1994[Abstract].
15.
Greenspan, SL,
Rowe JW,
Maitland LA,
McAloon-Dyke M,
and
Elahi D.
The pituitary-adrenal glucocorticoid response is altered by gender and disease.
J Gerentol
3:
M72-M77,
1993.
16.
Guidot, DM,
Stevens EE,
Repine MJ,
and
Lucca-Broco AE.
Intratracheal but not intravascular interleukin-1 causes acute edematous injury in isolated neutrophil-perfused rat lungs through oxygen radical-mediated mechanisms.
J Lab Clin Med
123:
605-609,
1994[ISI][Medline].
17.
Heuser, IJ,
Gotthardt U,
Schmider SJ,
Lammers C,
Dettling M,
and
Holsboer F.
Age-associated changes of pituitary-adrenocortical hormone regulation in humans: Importance of gender.
Neurobiol Aging
15:
227-231,
1994[ISI][Medline].
18.
Junker, K.
Glucocorticoid receptors of human mononuclear leukocytes in vitro.
J Clin Endocrinol Metab
57:
506-512,
1983[Abstract].
19.
Kay, M,
and
Makinodan T.
Relationship between aging and the immune system.
Prog Allergy
29:
134-181,
1981[Medline].
20.
Knudsen, PJ,
Dinarello CA,
and
Strom TB.
Glucocorticoids inhibit transcriptional and post transcriptional expression of interleukin-1 in U937 cells.
J Immunol
139:
4129-4134,
1987[Abstract].
21.
Lew, W,
Oppenheim JJ,
and
Matsushima K.
Analysis of the supression of IL-1
and IL-1
production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone.
J Immunol
140:
1895-1902,
1988
22.
Mandrup-Poulsen, T,
Zumsteg U,
Reimers J,
Pociot F,
Helqvist Morch LS,
Dinarello CA,
and
Nerup J.
Involvement of interleukin-1 and interleukin-1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitis.
Cytokine
5:
185-191,
1993[ISI][Medline].
23.
McKean, DJ,
Podzorski RP,
Bell MP,
Nilson AE,
Huntoon CJ,
Slack JS,
Dower SK,
and
Sims J.
Murine T helper cell-2 lymphocytes express Type I and Type II receptors, but only the type I receptor mediates costimulatory activity.
J Immunol
151:
3500-3510,
1993[Abstract].
24.
McMahan, CJ,
Slack JL,
Mosley B,
Cosman D,
Lupton SD,
Brunton LL,
Grubin CE,
Wignall JM,
Jenkins NA,
Camilynn IB,
Copeland NG,
Huebner LA,
Croce CM,
Cannizzarro LA,
Berlamin D,
Dower SK,
Spriggs M,
and
Sims JE.
A novel IL-1 receptor, cloned from B cell by mammalian expression, is expressed in many cell types.
EMBO J
10:
2821-2832,
1991[ISI][Medline].
25.
Ngai, PKM,
Ackermann F,
Wendt H,
Savoca R,
and
Bosshard HR.
Protein A antibody-capture ELISA (PACE): an ELISA format to avoid denaturation of surface absorbed antigens.
J Immunolog Methods
158:
267-276,
1993[ISI][Medline].
26.
Penton-Rol, G,
Orlando S,
Polentaurtti N,
Bernasconi S,
Muzio M,
Introna M,
and
Mantovani A.
Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 Type II receptor, with concomitant up-regulation of the Type I receptor and induction of incompletely spliced transcripts.
J Immunol
162:
2931-2938,
1999
27.
Rauschmayr, T,
Groves R,
and
Kupper TS.
Keratinocyte expression of the type 2 interleukin-1 receptor mediates local and specific inhibition of interleukin-1-mediated inflammation.
Proc Natl Acad Sci USA
94:
5814-5819,
1997
28.
Re, F,
Marco M,
De Rossi M,
Polentarutti N,
Giri JG,
Mantovani A,
and
Colotta F.
The type II "receptor" as a decoy target for interleukin-1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor.
J Exp Med
179:
739-743,
1994
29.
Rivier, C.
Stimulatory effect of interleukin-1
on the hypothalamic-pituitary-adrenal axis of the rat: influence of age, gender, and circulating sex steroids.
J Endocrinol
140:
365-372,
1994
30.
Rivier, C,
Chizzonite R,
and
Vale W.
In the mouse, activation of the hypothalamic-pituitary-adrenal axis by lipopolysaccharide (endotoxin) is mediated through interleukin-1.
Endocrinology
125:
2800-2805,
1989[Abstract].
31.
Saccani, S,
Polentarutti N,
Penton-Rol G,
Sims JE,
and
Montovani A.
Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo.
Cytokine
10:
773-780,
1998[ISI][Medline].
32.
Sapolsky, R,
Rivier C,
Yamamato G,
Plotsky P,
and
Vale W.
Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing hormone.
Science
238:
522-524,
1987
33.
Shingu, M,
Isayama T,
Naono T,
Nobunaga M,
Tomari K,
Horie K,
and
Goto Y.
Role of oxygen radicals and IL-6 and IL-1-dependent cartilage matrix degradation.
Inflammation
18:
613-623,
1994[ISI][Medline].
34.
Strober, W.
Preparation of human mononuclear cell populations and subpopulations.
In: Current Protocols in Immunology, edited by Coico C.. New York: John Wiley, 1996, p. 707-712.
35.
Svec, F,
Yearley J,
and
Harrison RW.
Progesterone enhances glucocorticoid dissociation from the AtT-20 cell glucocorticoid receptor.
Endocrinology
107:
566-572,
1980[ISI][Medline].
36.
Tanka, H,
Akama H,
Ichikawa Y,
Homma M,
and
Oshima H.
Glucocorticoid receptors in normal leukocytes: effects of age, gender, season, and plasma cortisol concentrations.
Clin Chem
37:
1715-1719,
1991
37.
Van der Poll, T,
Malefyt RW,
Coyle SM,
and
Lowry SF.
Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL-1) receptor type II, IL-10, and IL-13.
J Infect Dis
175:
118-122,
1997[ISI][Medline].
38.
Vannier, E,
de Wall Malefyt R,
Salazar-Montes A,
deTries JE,
and
Dinarello CA.
Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein.
Blood
87:
3307-3315,
1996
39.
Vannier, E,
Miller LC,
and
Dinarello CA.
Coordinated anti-inflammatory effects ofinterleukin-4: interleukin-4 suppresses interleukin-1 production but upregulates gene expression and synthesis of interleukin-1 receptor antagonist.
Proc Natl Acad Sci
89:
4076-4080,
1992
40.
Wilkinson, CW,
Peskind ER,
and
Raskind MA.
Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging.
Neuroendocrinology
65:
79-90,
1996.
This article has been cited by other articles:
![]() |
P H Wirtz, R von Kanel, N Rohleder, and J E Fischer Monocyte proinflammatory cytokine release is higher and glucocorticoid sensitivity is lower in middle aged men than in women independent of cardiovascular risk factors Heart, August 1, 2004; 90(8): 853 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Persson Aging Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R1 - R2. [Full Text] [PDF] |
||||
![]() |
W. J. Becker and J. G. Cannon Influence of barometric pressure on interleukin-1{beta} secretion Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2001; 280(6): R1897 - R1901. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |